Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
278.65 USD   -2.42%
12/07Amgen : When It Comes to Biosimilar Manufacturing, Heritage and Expertise Matter
PU
12/07Amgen : Investor Presentation December 2022
PU
12/07Amgen : Alliances Help Connect Patients with Lung Cancer to Precision Medicine Treatments
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2022 12/06/2022 12/07/2022 12/08/2022 12/09/2022 Date
284.91(c) 283.29(c) 285.76(c) 285.57(c) 278.65 Last
3 274 673 2 479 398 2 492 628 1 769 790 2 205 856 Volume
-0.21% -0.57% +0.87% -0.07% -2.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 26 241 M - -
Net income 2022 6 552 M - -
Net Debt 2022 26 379 M - -
P/E ratio 2022 23,0x
Yield 2022 2,78%
Sales 2023 27 164 M - -
Net income 2023 7 839 M - -
Net Debt 2023 24 245 M - -
P/E ratio 2023 18,7x
Yield 2023 2,99%
Capitalization 149 B 149 B -
EV / Sales 2022 6,67x
EV / Sales 2023 6,37x
Nbr of Employees 24 200
Free-Float 99,8%
More Financials
Company
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (93.5%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (6.5%): primarily royalties. The United States account for 66.5% of net sales. 
Sector
Pharmaceuticals
Calendar
02/02Earnings Release
More about the company
Ratings of Amgen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about AMGEN INC.
12/07Amgen : When It Comes to Biosimilar Manufacturing, Heritage and Expertise Matter
PU
12/07Amgen : Investor Presentation December 2022
PU
12/07Amgen : Alliances Help Connect Patients with Lung Cancer to Precision Medicine Treatments
PU
12/06Oppenheimer Adjusts Amgen Price Target to $310 From $300, Maintains Outperform Rating
MT
12/06Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
RE
12/05Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
RE
12/05Better days ahead?
MS
12/05Juno Therapeutics Requests That The Supreme Court Wait To Make A Decision On Its Writte..
AQ
12/05Amgen : WCIRDC Presentation
PU
12/05Transcript : Amgen Inc. - Special Call
CI
12/05Johnson & Johnson's Janssen Global Services Unit Says No Plans to Bid for Horizon Thera..
MT
12/03Amgen says experimental obesity drug has promising durability
RE
12/03J&J unit says does not intend to bid for Horizon Therapeutics
RE
12/03J&J unit says does not intend to bid for Horizon Therapeutics
RE
12/03Transcript : Amgen Inc. Presents at 20(th) WCIRDC Hybrid Conference, Dec-03-2..
CI
More news
News in other languages on AMGEN INC.
12/07Aktien New York: Dow vorsichtig stabilisiert - Nasdaq nochmals schwächer
12/05Amgen annonce des résultats encourageants pour son traitement contre l’obésité
12/05L'unité Janssen Global Services de Johnson & Johnson ne prévoit pas de faire une offre ..
12/05USA-Les valeurs à suivre à Wall Street (actualisé)
12/03Amgen dice que un fármaco experimental contra la obesidad tiene una duración prometedor..
More news
Analyst Recommendations on AMGEN INC.
More recommendations
ETFs positioned on AMGEN INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AGFiQ US Market Neutral Anti-Beta Fund - USD20.12%1.60%United_States
VanEck Vectors Biotech ETF - USD14.6%-1.38%United_States
Invesco Nasdaq Biotechnology ETF - USD7.85%-1.19%-United_States
IShares Biotechnology ETF - USD7.84%-0.93%-NC
IShares Nasdaq US Biotechnology (D) - USD7.77%-0.75%United_States
More ETFs positioned on AMGEN INC.
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Last Close Price 278,65 $
Average target price 260,06 $
Spread / Average Target -6,67%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.27.02%152 374
JOHNSON & JOHNSON2.73%463 286
ELI LILLY AND COMPANY34.60%353 267
ABBVIE INC.20.43%293 450
PFIZER, INC.-12.31%290 657
NOVO NORDISK A/S22.08%287 434